NCT05226780View on ClinicalTrials.gov

Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Interventions
DRUG

NBI-921352

Administered orally

Trial Locations (4)

14642

University of Rochester, Rochester

20010

Children's National Hospital, Washington D.C.

76104

Cook Children's Medical Center, Fort Worth

94143

UCSF Medical Center, San Francisco

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY